BRAF and cancer: However, due to the broad coverage of the present biomarker panel, not only cancers harboring these features were biomarker positive, but also the majority of MSS tumors with wild-type BRAF. It is essential that a diagnostic biomarker panel adequately "represents" the entire large bowel, in order to detect all pheno- and geno-typically different colorectal tumors.